Induction for CV patient Flashcards
Milrinone MOA
phosphodiesterase 3 inhibitor; prevent the breakdown of cAMP
Causes positive inotropic action and vasodilation without producing tachycardia
Milrinone dosing
start infusion at 0.375 mcg/min up to .75 mcg/min
Dobutamine MOA
synthetic sympathomimetic amine
Primarily a beta 1 agonist with some B2 effects
Increases: inotropy, cardiac output BP may slightly increase or remain the same
Decreases: SVR due to peripheral vasodilation; pulmonary artery pressure
Dobutamine dosing
Dosing: 0.5-20 mcg/kg/min
Norepi causes increased _______ d/t increase in ________BP.
-coronary artery perfusion
-diastolic
Nitro MOA
direct vasodilator – venous»_space; arterial; caused by an induced increase of vascular nitric oxide
Nitro concentration dosing
nitro “lite” vials obtained from pharmacy come 40 mcg/mL in a 10 mL vial dose in increments of 40 mcg at a time
Nitro infusion dosing
is 400 mcg/mL in a 250 mL bottle infusion rate is typically started at 5 mcg/min in heart room
Esmolol MOA and metabolism
beta 1 selective antagonist
Unique metabolism: nonspecific plasma esterases
Esmolol uses and onset/side effects
Has an extremely quick (2 min or less) onset and short half-life useful to transiently treat elevated HR without carrying lasting effects that may cause subsequent low BP
Often used alongside induction agents prevent an increase in HR during laryngoscopy
Esmolol concentration
10 mg/mL in a 10 mL vial administer in increments of 10-30 mg at a time
Vasopressin MOA
endogenous hormone produced in the hypothalamus, stored in posterior pituitary gland; release is stimulated by increased osmolality and hypovolemia
Aka ADH
Vasopressin dosing
Dosing: comes in vials 20 units/mL mix one mL with 19 mL NS for a concentration of 1 unit/mL dose in increments of 1 unit at a time
Infusion dose: 0.04 units/min
Epi “heavy”
Epi “heavy” 100 mcg/mL – mix 1 mL vial of epi in 9 mL of NS dilutent
Epi “light”
” 10 mcg/ml- mix 1 mL of epi “heavy” mixture into 9 mL of NS dilutent